EGFR and non-small cell lung carcinoma: Given the small sample size, we were not able to detect statistically significant differences, but we saw that females had a higher frequency of EGFR mutations overall (32/99, 32.32% vs. 8/53, 15.09%) and seen in both HR+ NSCLC (10/25, 40.00% vs. 1/6, 16.67%) and in HR- NSCLC (22/74, 29.73% vs. 7/47, 14.89%).